{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:08:44Z","timestamp":1779358124951,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005719","name":"Dicle University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005719","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-acting growth hormone preparations have the potential to improve treatment compliance by reducing the frequency of injections. The aim of this study was to evaluate the efficacy and safety of weekly somatrogon treatment in patients with pediatric growth hormone deficiency (GHD) under real-world conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with GHD aged 3\u201318 years who had been receiving somatrogon therapy for at least 6 months were included in the study. Anthropometric measurements, insulin-like growth factor-1 (IGF-1), bone age\/chronological age (BA\/CA) ratio, and drug-related adverse events were evaluated at baseline and at the final follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 39 patients with a mean age of 12.90\u2009\u00b1\u20091.63 years were included. The mean treatment duration was 11.31\u2009\u00b1\u20092.72 months (min\u2013max: 6.36\u201316.92). The mean annual height gain was 10.07\u2009\u00b1\u20090.61\u00a0cm, and the \u0394 height SDS was 0.64. No significant change was observed in the BA\/CA ratio (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.2). The mean baseline IGF-1 SDS was \u2212\u20090.61\u2009\u00b1\u20091.15, increasing to 0.75\u2009\u00b1\u20091.26 at the final follow-up (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). In 5 of 39 patients (12.8%), IGF-1 SDS exceeded\u2009+\u20092 SDS, requiring dose reduction. No serious adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on our real-world data, weekly somatrogon therapy provided an effective growth response and was well tolerated in pediatric patients with GHD. In most cases, mean IGF-1 levels remained within the normal range. However, IGF-1 levels may be elevated, particularly in pubertal patients. These findings support somatrogon as a safe and effective early treatment option in routine clinical practice, although larger and longer-term studies are required to confirm long-term safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-026-04658-9","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:40:02Z","timestamp":1779356402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and safety of weekly somatrogon treatment in turkish children with growth hormone deficiency: a real-world cohort study"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4574-2434","authenticated-orcid":false,"given":"Tahsin","family":"Gider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-0977","authenticated-orcid":false,"given":"Edip","family":"Unal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6889-4504","authenticated-orcid":false,"given":"Servet","family":"Yel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-358X","authenticated-orcid":false,"given":"Bar\u0131\u015f","family":"Kolba\u015f\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6637-1896","authenticated-orcid":false,"given":"H\u00fcseyin","family":"D\u00fczg\u00fcn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"4658_CR1","doi-asserted-by":"crossref","unstructured":"Richmond E, Rogol AD. Testing for growth hormone deficiency in children. Growth Horm IGF Res. 2020; 50: 57\u201360.","DOI":"10.1016\/j.ghir.2019.12.002"},{"key":"4658_CR2","doi-asserted-by":"crossref","unstructured":"Ranke MB. Short and long-term effects of growth hormone in children and adolescents with GH deficiency. Front Endocrinol. 2021; y12:720419.","DOI":"10.3389\/fendo.2021.720419"},{"key":"4658_CR3","doi-asserted-by":"crossref","unstructured":"Savendahl L, Polak M, Backeljauw P, Blair JC, Miller BS, Rohrer TR, et al. Long-term safety of growth hormone treatment in childhood: two large observational studies: nordinet IOS and answer. J Clin Endocrinol Metab. 2021; 106(6):1728\u201341.","DOI":"10.1210\/clinem\/dgab080"},{"key":"4658_CR4","doi-asserted-by":"crossref","unstructured":"Tidblad A, Bottai M, Kieler H, Albertsson-Wikland K, Sa vendahl L. Association of childhood growth hormone treatment with long-term cardiovascular morbidity. JAMA Pediatr. 2021;175(2):e205199.","DOI":"10.1001\/jamapediatrics.2020.5199"},{"key":"4658_CR5","doi-asserted-by":"crossref","unstructured":"Swerdlow AJ, Cooke R, Albertsson-Wikland K, Borgstrom B, Butler G, Cianfarani S, et al. Description of the SAGhE Cohort: a Large European study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone. Horm Res Paediatr. 2015;84(3):172\u201383.","DOI":"10.1159\/000435856"},{"key":"4658_CR6","doi-asserted-by":"crossref","unstructured":"Savendahl L, Polak M, Backeljauw P, Blair J, Miller BS, Rohrer TR, et al. Treatment of children with GH in the United States and Europe: long-term follow-up from NordiNet(R) IOS and answer program. J Clin Endocrinol Metab. 2019;104(10):4730\u201342.","DOI":"10.1210\/jc.2019-00775"},{"key":"4658_CR7","doi-asserted-by":"crossref","unstructured":"Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ. 2011;342:c7157.","DOI":"10.1136\/bmj.c7157"},{"key":"4658_CR8","doi-asserted-by":"crossref","unstructured":"Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, Kim HS, Ko C, Malievskiy O, Cara JF, Roland CL, Taylor CT, Valluri SR, Wajnrajch MP, Pastrak A, Miller BS. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2717-e2728. doi: 10.1210\/clinem\/dgac220. PMID: 35405011; PMCID: PMC9202717.","DOI":"10.1210\/clinem\/dgac220"},{"key":"4658_CR9","doi-asserted-by":"crossref","unstructured":"Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr. 2013;79(4):189\u201396.","DOI":"10.1159\/000350251"},{"key":"4658_CR10","doi-asserted-by":"crossref","unstructured":"Brod M, Alolga SL, Beck JF, Wilkinson L, H\u00f8jbjerre L, Rasmussen MH. Understanding burden of illness for child growth hormone deficiency. Qual Life Res. 2017; 26(5): 1673\u201386.","DOI":"10.1007\/s11136-017-1529-1"},{"key":"4658_CR11","doi-asserted-by":"crossref","unstructured":"Graham S, Auyeung V, Weinman J. Exploring potentially modifiable factors that influence treatment non-adherence amongst pediatric growth hormone deficiency: a qualitative study. Patient Prefer Adherence. 2020; 14: 1889\u201399.","DOI":"10.2147\/PPA.S268972"},{"key":"4658_CR12","doi-asserted-by":"crossref","unstructured":"Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld RG, Hoshino Y, Okayama A, Shima D, Gomez R, Pastrak A, Castellanos O. Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin\u00ae) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study. Horm Res Paediatr. 2022;95(3):275\u2013285. doi: 10.1159\/000524600. Epub 2022 Apr 13. PMID: 35417909; PMCID: PMC9533447.","DOI":"10.1159\/000524600"},{"key":"4658_CR13","doi-asserted-by":"crossref","unstructured":"Cutfield WS, Derraik JG, Gunn AJ, Reid K, Delany T, Robinson E, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One. 2011; 6(1): e16223.","DOI":"10.1371\/journal.pone.0016223"},{"key":"4658_CR14","doi-asserted-by":"crossref","unstructured":"Hughes IP, Choong C, Rath S, Atkinson H, Cotterill A, Cutfield W, et al. Early cessation and non-response are important and possibly related problems in growth hormone therapy: an OZGROW analysis. Growth Horm IGF Res. 2016; 29: 63\u201370.","DOI":"10.1016\/j.ghir.2016.04.006"},{"key":"4658_CR15","unstructured":"Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF, et al. Growth hormone research society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016; 174(6): C1\u20138."},{"key":"4658_CR16","doi-asserted-by":"crossref","unstructured":"Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969 Jun;44(235):291\u2013303. doi: 10.1136\/adc.44.235.291. PMID: 5785179; PMCID: PMC2020314.","DOI":"10.1136\/adc.44.235.291"},{"key":"4658_CR17","doi-asserted-by":"crossref","unstructured":"Zelinska N, Iotova V, Skorodok J, et al. Long-acting C-terminal peptide-modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab. 2017;102(5):1578\u20131587.","DOI":"10.1210\/jc.2016-3547"},{"key":"4658_CR18","doi-asserted-by":"crossref","unstructured":"Zadik Z, Zelinska N, Iotova V, et al. Results from an open-label extension of the phase 2 dose finding study of once weekly somatrogon vs daily genotropin in pediatric patients with growth hormone deficiency (GHD). J Endocr Soc. 2021;5(Suppl_1):A684-A685.","DOI":"10.1210\/jendso\/bvab048.1395"},{"key":"4658_CR19","doi-asserted-by":"crossref","unstructured":"Demir K, \u00d6zen S, Konak\u00e7\u0131 E, Ayd\u0131n M, Darendeliler F. A Comprehensive Online Calculator for Pediatric Endocrinologists: \u00c7EDD \u00c7\u00f6z\u00fcm\/TPEDS Metrics. J Clin Res Pediatr Endocrinol. 2017 Jun 1;9(2):182\u2013184. doi: 10.4274\/jcrpe.4526. Epub 2017 Apr 26. PMID: 28443820; PMCID: PMC5463294.","DOI":"10.4274\/jcrpe.4526"},{"key":"4658_CR20","doi-asserted-by":"crossref","unstructured":"Milner GR, Levick RK, Kay R. Assessment of bone age: a comparison of the Greulich and Pyle, and the Tanner and Whitehouse methods. Clin Radiol. 1986 Mar;37(2):119\u2009\u2212\u200921. doi: 10.1016\/s0009-9260(86)80376-2. PMID: 3698492.","DOI":"10.1016\/S0009-9260(86)80376-2"},{"key":"4658_CR21","doi-asserted-by":"crossref","unstructured":"Zadik Z, Zelinska N, Iotova V, Skorodok Y, Malievsky O, Mauras N, Valluri SR, Pastrak A, Rosenfeld R. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment. J Pediatr Endocrinol Metab. 2023 Feb 3;36(3):261\u2013269. doi: 10.1515\/jpem-2022-0359. PMID: 36732285.","DOI":"10.1515\/jpem-2022-0359"},{"key":"4658_CR22","doi-asserted-by":"crossref","unstructured":"Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld RG, Hoshino Y, Okayama A, Ebata N, Hosoi M, Nakamuta S, Gomez R, Pastrak A, Castellanos O. Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study. Endocr J. 2025 Oct 31. doi: 10.1507\/endocrj.EJ24-0625. Epub ahead of print. PMID: 41183961.","DOI":"10.1507\/endocrj.EJ24-0625"},{"key":"4658_CR23","doi-asserted-by":"crossref","unstructured":"Awad MH, Ghanim R, Eladl R, Mughal Z, Mustafa M. Real-World Efficacy of Weekly Somatrogon on Growth and Bone Health in Pediatric Growth Hormone Deficiency: A 12-Month Retrospective Cohort Study. J Clin Res Pediatr Endocrinol. 2025 Sep 30. doi: 10.4274\/jcrpe.galenos.2025.2025-6-24. Epub ahead of print. PMID: 41025548.","DOI":"10.4274\/jcrpe.galenos.2025.2025-6-24"},{"key":"4658_CR24","doi-asserted-by":"crossref","unstructured":"Katsoudas S, Tsitsekli E, Pichlinski I, Techlemetzi N, Galanopoulou E, Polychroni I, Zosi P. Comparative Efficacy of Once-Weekly Somatrogon Versus Daily Growth Hormone Therapy in Children With Idiopathic Growth Hormone Deficiency: A Real-World Retrospective Study From Greece. Cureus. 2025 Apr 25;17(4):e82998. doi: 10.7759\/cureus.82998. PMID: 40416193; PMCID: PMC12103926.","DOI":"10.7759\/cureus.82998"},{"key":"4658_CR25","doi-asserted-by":"crossref","unstructured":"Tamaro G, Rodaro C, Fachin A, Fabretto A, Tornese G. Two-year real-world experience with somatrogon in children and adolescents with growth hormone deficiency. Front Endocrinol (Lausanne). 2026 Jan 28;17:1685851. doi: 10.3389\/fendo.2026.1685851. eCollection 2026","DOI":"10.3389\/fendo.2026.1685851"},{"key":"4658_CR26","doi-asserted-by":"crossref","unstructured":"\u015een K\u00fc\u00e7\u00fck K, G\u00fcne\u015f S, Din\u00e7er M, \u00d6zt\u00fcrk S, \u00dcn\u00fcvar T, An\u0131k A. Once-Weekly Somatrogon in Pediatric Growth Hormone Deficiency: Real-World Efficacy, Safety, and Quality-of-Life Findings.J Clin Res Pediatr Endocrinol. 2026 Mar 17. doi: 10.4274\/jcrpe.galenos.2026.2025-11-4. Online ahead of print.","DOI":"10.4274\/jcrpe.galenos.2026.2025-11-4"},{"key":"4658_CR27","doi-asserted-by":"crossref","unstructured":"Pampanini V, Deodati A, Inzaghi E, Cianfarani S. Long-Acting Growth Hormone Preparations and Their Use in Children with Growth Hormone Deficiency. Horm Res Paediatr. 2023;96(6):553\u2013559. doi: 10.1159\/000523791. Epub 2022 Feb 25. PMID: 35220308.","DOI":"10.1159\/000523791"},{"key":"4658_CR28","doi-asserted-by":"crossref","unstructured":"Woelfle J, Kreitschmann-Andermahr I, Strasburger CJ, Pittrow DB, Pausch C, Schnabel D. First 100 patients receiving long-acting growth hormone therapy: real-world evaluation from INSIGHTS-GHT registry. Orphanet J Rare Dis. 2025 Jul 23;20(1):372. doi: 10.1186\/s13023-025-03898-8. PMID: 40702497; PMCID: PMC12285006.","DOI":"10.1186\/s13023-025-03898-8"},{"key":"4658_CR29","doi-asserted-by":"crossref","unstructured":"\u015een K\u00fc\u00e7\u00fck K, Tuzcu G, An\u0131k A. Reversible Injection-Site Lipoatrophy Induced by Long-Acting Growth Hormone (Somatrogon) in Pediatric Growth Hormone Deficiency: A Case Series. J Clin Res Pediatr Endocrinol. 2025 Nov 20. doi: 10.4274\/jcrpe.galenos.2025.2025-10-16. Epub ahead of print. PMID: 41261869.","DOI":"10.4274\/jcrpe.galenos.2025.2025-10-16"},{"key":"4658_CR30","doi-asserted-by":"crossref","unstructured":"B\u00fcy\u00fckgebiz A, Demir A. Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone. Children (Basel). 2025 Jan 4;12(1):58. doi: 10.3390\/children12010058. PMID: 39857889; PMCID: PMC11764380.","DOI":"10.3390\/children12010058"},{"key":"4658_CR31","doi-asserted-by":"crossref","unstructured":"Cohen-Sela E, Oren A, Perl L, Regev R, Segev Becker A, Eyal O, Mazor-Aronovitch K, Tenenbaum A, Rachmiel M, Lebenthal Y, Brener A. Introduction of Somatrogon in Pediatric Growth Hormone Deficiency: Real-World Insights From a National Survey of Pediatric Endocrinologists. Endocr Pract. 2025 Nov 13:S1530-891X(25)01272-8. doi: 10.1016\/j.eprac.2025.11.008. Epub ahead of print. PMID: 41241277","DOI":"10.1016\/j.eprac.2025.11.008"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04658-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04658-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04658-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:40:22Z","timestamp":1779356422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04658-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4658"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04658-9","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the rules of Declaration of Helsinki and approved by the Institutional Ethics Committee of Dicle University Faculty of Medicine Hospital (Approval No. 14, November 26, 2025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"187"}}